A nano antibody against RPL19 and its application

By optimizing immune strategies and molecular biology technical steps, a high-quality nanoantibodies phage display library was constructed, which solved the difficulties in extraction and amplification during nanoantibodies screening, and achieved efficient screening of nanoantibodies against RPL19, improving antibody screening Efficiency and success rate.

CN118459580BActive Publication Date: 2024-11-26NINGXIA MEDICAL UNIVERSITY GENERAL HOSPITAL
View PDF 3 Cites 0 Cited by

Patent Information

Application Number
CN202410648286.8
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-05-23
Publication Date
2024-11-26
Estimated Expiration
2044-05-23

AI Technical Summary

Technical Problem

In the process of constructing the nanoantibody phage display library, there are technical difficulties in extracting and purifying lymphocytes, total RNA, and amplifying antibody variable region genes, resulting in low antibody screening efficiency and success rate.

Method used

By optimizing immune strategies, lymphocyte isolation, total RNA extraction, cDNA synthesis and antibody variable region gene amplification steps, a high-quality and highly diverse nanoantibody phage display library is constructed to achieve high-affinity nanobody screening for specific antigens.

Benefits of technology

An efficient, stable and reliable nano-antibody screening was achieved, which improved the efficiency and success rate of antibody screening, and screened out nano-antibody with high affinity anti-RPL19.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118459580B_ABST
    Figure CN118459580B_ABST
Patent Text Reader

Abstract

The invention discloses a nano antibody against RPL19, belonging to the technical field of immunology. The nano antibody against RPL19 first needs to extract lymphocytes from an immunized animal, and separate total RNA therefrom, further synthesize cDNA by reverse transcription, and amplify antibody variable region genes, and finally insert these gene fragments into a phage display vector to form a phage display library. The nano antibody against RPL19 constructs a high-quality, high-diversity nano antibody phage display library by optimizing the immune strategy, lymphocyte separation, total RNA extraction, cDNA synthesis, and antibody variable region gene amplification, and is successfully applied to the screening of high-affinity nano antibodies against specific antigens. At the same time, the construction method of the nano antibody against RPL19 is efficient, stable, and reliable.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the technical field of immunology, and specifically relates to an anti-RPL19 nanobody and an application thereof. Background Art

[0002] In the field of biotechnology, antibodies, as an important biological molecule, have broad application prospects in disease diagnosis, treatment and drug development. The traditional method of antibody production mainly relies on hybridoma technology of immunized animals. However, this technology has problems such as high cost, complex operation and low antibody affinity. In recent years, with the development of genetic engineering and molecular biology technology, phage display technology has become a new antibody screening method, which can screen antibody fragments with specific binding activity with high throughput and high efficiency.

[0003] Phage display technology is a technology that fuses foreign proteins or peptide fragments with phage surface proteins and uses the biological characteristics of phages for screening and enrichment. This technology is particularly suitable for screening antibody variable region genes, because the antibody variable region is the key site for antibody-antigen binding and determines the specificity and affinity of the antibody.

[0004] However, there are many technical difficulties in the process of constructing nanoantibody phage display libraries, such as how to efficiently extract and purify lymphocytes, how to effectively extract and purify total RNA, how to accurately amplify antibody variable region genes, etc. Therefore, developing an efficient, stable and reliable method for constructing nanoantibody phage display libraries is of great significance for improving the efficiency and success rate of antibody screening. Summary of the invention

[0005] The purpose of the present invention is to provide an anti-RPL19 nanobody and its application in view of the existing problems.

[0006] The present invention is achieved through the following technical solutions:

[0007] A nanobody against RPL19, the amino acid sequence of the nanobody is shown in SEQ ID NO:1.

[0008] A nucleic acid, wherein the nucleic acid is: a nucleic acid encoding the antibody according to claim 1.

[0009] An expression vector comprising the above nucleic acid.

[0010] A host cell comprising the above expression vector.

[0011] Compared with the prior art, the present invention has the following advantages:

[0012] The present invention first needs to extract lymphocytes from the immunized animal, and separate total RNA therefrom, further synthesize cDNA by reverse transcription, and amplify the antibody variable region gene, and finally insert these gene fragments into the phage display vector to form a phage display library. The anti-RPL19 nanobody constructs a high-quality, high-diversity nanobody phage display library by optimizing the immune strategy, lymphocyte separation, total RNA extraction, cDNA synthesis, and antibody variable region gene amplification steps, and is successfully applied to the screening of high-affinity nanoantibodies against specific antigens. At the same time, the construction method of the anti-RPL19 nanobody is efficient, stable, and reliable. BRIEF DESCRIPTION OF THE DRAWINGS

[0013] In order to more clearly illustrate the technical solutions of the embodiments of the present application, the drawings required for use in the embodiments will be briefly introduced below. It should be understood that the following drawings only show certain embodiments of the present application and therefore should not be regarded as limiting the scope. For ordinary technicians in this field, without paying any creative work, other related drawings can be obtained based on these drawings and they also belong to the protection scope of the present application.

[0014] Figure 1 Flow chart of the construction and screening process of the Nanobody phage display library provided in the examples of the present application. DETAILED DESCRIPTION

[0015] Figure 1 Flow chart of the construction and screening process of the Nanobody phage display library provided in the embodiments of this application. Figure 1 , the preparation method comprises the following steps:

[0016] In order to further explain the present invention, it is described below in conjunction with the following specific embodiments.

[0017] Example 1

[0018] Construction and screening of nanobody phage display library

[0019] (1) Immunity of alpacas

[0020] A healthy adult alpaca was selected, and the recombinant RPL19 antigen (CUSBIO, catalog number: CSB-YP020160HU) was mixed with Freund's adjuvant at a ratio of 1:1. The alpaca was immunized by multiple subcutaneous injections at the back at 7 μg / kg for a total of four immunizations with an interval of 2 weeks. Afterwards, the alpaca's peripheral blood was collected for the construction of a phage display library.

[0021] (2) Isolation of alpaca lymphocytes

[0022] 1) Add EDTA.2K anticoagulant (10×) (Solarbio, catalog number: G0280) to the fresh alpaca peripheral blood collected at 0.12 ml per ml of blood, and separate lymphocytes using a camel peripheral blood lymphocyte separation solution kit (Solarbio, catalog number: P5750);

[0023] 2) Dilute whole blood with an equal volume of PBS, add 3 ml of separation solution to a centrifuge tube, spread the diluted blood evenly on the surface of the separation solution, keep the interface between the two liquid surfaces clear, centrifuge at room temperature, 800g in a horizontal rotor, centrifuge for 20 minutes, slowly and carefully pipette the lymphocyte layer into a 15 ml centrifuge tube, and wash the lymphocyte layer cells with 10 ml of PBS or cell washing solution;

[0024] 3) Centrifuge at 250 g for 10 min, discard the supernatant, resuspend the cells in 5 ml of PBS, centrifuge at 250 g for 10 min, discard the supernatant, resuspend the cells in 5 ml of PBS, centrifuge at 250 g for 10 min, resuspend the cells for later use.

[0025] (3) Total RNA extraction

[0026] Total RNA was extracted using a magnetic bead blood total RNA extraction kit (Servicebio, catalog number: G3611).

[0027] 1) Add DTT Solution to Buffer BRL, add 40 μl DTT Solution per 1 mL Buffer, so that the final concentration of DTT Solution is 4%;

[0028] 2) 1.5 mL containing 1×10 7 The lymphocyte cell suspension was centrifuged at 1450 g at 4 °C for 10 min, and the supernatant was completely aspirated to avoid aspirating the cell pellet;

[0029] 3) Add 600ul of Buffer BRL containing DDT Solution to resuspend the cells, add 1ml of isopropanol and mix by inverting 3 times, then add 20ul of vortexed SweMag Beads, use a pipette to gently pipette until the beads are evenly dispersed, and let stand at room temperature for 10min. During the standing period, use a pipette to mix once every 2min;

[0030] 4) Move the centrifuge tube to the magnetic stand and let it stand for 30 seconds. Then slowly turn the centrifuge tube upside down several times together with the magnetic stand to wash off the magnetic beads remaining on the tube wall. When the supernatant is clear, discard the supernatant;

[0031] 5) Add 500 μl Buffer RW1, remove the magnetic stand, use a pipette to pipette until the magnetic beads are evenly dispersed, move the centrifuge tube to the magnetic stand and let it stand for 30 seconds, then slowly turn the centrifuge tube upside down several times together with the magnetic stand to remove the magnetic beads remaining on the tube wall, and discard the supernatant after it becomes clear;

[0032] 6) Add 500 μl Buffer RW2, remove the magnetic stand, use a pipette to blow until the magnetic beads are evenly dispersed, move the centrifuge tube to the magnetic stand and let it stand for 30 seconds, then slowly turn the centrifuge tube upside down several times together with the magnetic stand to wash off the magnetic beads remaining on the tube wall, and discard the supernatant after it becomes clear;

[0033] 7) Remove the magnetic stand and add 100 μl of DNase reaction solution containing 10 μl 10× DNase Buffer, 10 μl DNase and 80 μl Nuclease-free Water to the centrifuge tube containing the magnetic beads for DNase digestion. Use a pipette to gently pipette until the magnetic beads are evenly dispersed. Let stand at room temperature for 15 minutes, and use a pipette to mix every 5 minutes.

[0034] 8) After digestion, add 600 μl Buffer RW2 and use a pipette to pipette until the magnetic beads are evenly dispersed. Move the centrifuge tube to the magnetic stand and let it stand for 30 seconds. Then slowly turn the centrifuge tube upside down several times together with the magnetic stand to wash off the magnetic beads remaining on the tube wall. When the supernatant is clear, aspirate and discard the supernatant;

[0035] 9) Add 500 μl Buffer RW2, remove the magnetic stand, use a pipette to blow until the magnetic beads are evenly dispersed, move the centrifuge tube to the magnetic stand and let it stand for 30 seconds, then slowly turn the centrifuge tube upside down several times together with the magnetic stand to wash off the magnetic beads remaining on the tube wall, and discard the supernatant after it becomes clear;

[0036] 10) Open the centrifuge tube cap and air dry at room temperature for 7 minutes to allow the ethanol to evaporate completely and prevent the magnetic beads from over-drying; remove the magnetic rack, add 50μl Nuclease-free Water to the centrifuge tube, use a pipette to gently blow until the magnetic beads are evenly dispersed, and let stand at room temperature for 5 minutes; move the centrifuge tube to the magnetic rack until all the magnetic beads are adsorbed to the tube wall, and aspirate the supernatant into a new Nuclease-free centrifuge tube. Adjust the concentration to 1μg / μl for gel electrophoresis detection.

[0037] (4) Reverse transcription to synthesize cDNA

[0038] use IIOne-Step gDNA Removal and cDNA Synthesis SuperMix (TransGen Biotech, Catalog No.: AH311-02), using the RNA obtained in step (3) as a template for reverse transcription of cDNA.

[0039] (5) Antibody variable region gene amplification

[0040] The cDNA obtained by reverse transcription was used as a template for PCR reaction, and the amplification was carried out for two rounds.

[0041] The primer sequences for the first round of PCR are as follows:

[0042] 5' Primer (Forward Primer): CAGGTGCAGCTGCAGGAGTCTGG

[0043] 3' Primer (Reverse Primer): GATGGTGGGAAGATGAAGGCT

[0044] The PCR reaction conditions and procedures were as follows: 95°C for 5 min; 95°C for 30 s, 57°C for 30 s, 72°C for 30 s, 30 cycles; 72°C for 7 min.

[0045] The band of about 700 bp was recovered using an agarose gel recovery kit, and the nucleic acid concentration was finally adjusted to 5 ng / μl with water.

[0046] The primer sequences for the second round of PCR are as follows:

[0047] VHH-Back: GATGTGCAGCTGCAGGAGTCTGGRGGAGG

[0048] VHH-For:CTAGTGCGGCCGCTGGAGACGGTGACCTGGGT

[0049] The PCR reaction conditions and procedures were as follows: 95°C for 5 min; 95°C for 30 s, 55°C for 30 s, 72°C for 30 s, 15

[0050] Cycle; 72°C for 7 min.

[0051] Purify the PCR product using a PCR product recovery kit.

[0052] (6) Vector construction

[0053] 1) pMES4 (purchased from Biovector) and the second PCR product were double-digested with PstI and BstEII, respectively. 1.5 μg of the digested vector and 450 ng of the second PCR product were taken, 15 μl of T4 DNA ligase was added, and the buffer and water were supplemented to a total volume of 150 μl. The ligation was carried out at 16°C overnight and the ligation product was recovered;

[0054] 2) Use a PCR product recovery kit to recover the product and elute with 20 μl of water.

[0055] The results of double restriction enzyme digestion of pMES4 vector were detected by 1% agarose electrophoresis gel.

[0056] (7) Electroporation and storage capacity determination

[0057] 1) Take 10 μl of the purified ligation product, add it to a pre-cooled electroporation cup containing 50 μl of E. coli TG1 competent cells, place it in an electroporator for electrotransformation, take out the electroporation cup, revive and culture the transformants;

[0058] 2) Randomly select clones and perform colony PCR identification.

[0059] The library capacity was calculated based on the PCR positive rate (library capacity = number of clones × dilution factor × PCR positive rate × 10).

[0060] (8) Phage amplification

[0061] 1) Take the revived bacterial solution and inoculate it into YT-AG medium, and culture it at 37°C and 200 rpm until the culture OD600 = 0.5;

[0062] 2) Take out 10 ml of bacterial solution and add 4×10 10 VCSM13, static infection at 37°C for 30 min;

[0063] 3) Centrifuge at 4000 rpm for 10 min at room temperature, remove the supernatant, resuspend the cells in 2×YT-AK medium (containing ampicillin and kanamycin), and culture at 37°C, 200 rpm overnight;

[0064] 4) Centrifuge and take the supernatant into a 40 ml tube, add 10 ml PEG / NaCl (20% / 2.5 M) solution and mix thoroughly, centrifuge and discard the supernatant, wash the precipitate with 1 ml ice PBS and centrifuge, take the supernatant 250 μl pre-cooled PEG / NaCl, mix thoroughly, wash and resuspend.

[0065] Determine the phage titer: culture TG1 to OD600 = 0.4, dilute the phage in a gradient manner with LB medium, take the multiple dilutions of phage TG1 culture and mix them, observe the plaque formation in the culture plate the next day, count the plaques on the dilution gradient plates with a number of 30-300 and calculate the phage titer (pfu) according to the following formula.

[0066] Phage titer (pfu / ml) = dilution factor × number of plaques × 100

[0067] (9) Nanoantibody Screening

[0068] Positive clones were screened with antigen by ELISA.

[0069] 1) Coat the ELISA plate with antigen, block with 5% BSA, and wash with PBST;

[0070] 2) Add 100 μl of phage supernatant to each well and incubate at 37°C for 1 h;

[0071] 3) Discard the supernatant, add HRP-labeled mouse anti-M13 secondary antibody, and place at 37°C for 1 hour;

[0072] 4) Discard the supernatant, add TMB solution, incubate at room temperature for 5 h, add 2 M sulfuric acid stop solution to each well, and read the results at 450 nm using a microplate reader.

[0073] (10) Expression and purification of nanobodies in Escherichia coli

[0074] The clones with positive phage ELISA results were selected, the plasmids were extracted and transformed into the BL21 competent cells, the nanobody protein expression was induced with IPTG, the supernatant (periplasmic extract) was collected, and the periplasmic extract was dialyzed into PBS, purified using Ni-NTA resin, eluted and collected using different concentrations of imidazole, the collected samples were analyzed by reduced protein electrophoresis, and finally the nanobody was dialyzed into PBS.

[0075] Through alpaca immunization, cell separation, phage library construction, and nanoantibody screening, nanoantibodies against RPL19 were screened. The sequencing results were analyzed using VectorNTI software to analyze the antibody light chain and heavy chain genes to determine the framework regions (FR) and complementary determining regions (CDR) of the variable regions.

[0076] A preferred embodiment of the nanobody screened by the present invention is named 2F5. Through DNA sequencing, the amino acid sequence of the nanobody is shown in SEQ ID NO.1, wherein the amino acid sequence of positions 1-25 is FR1, the amino acid sequence of positions 26-33 is CDR1, the amino acid sequence of positions 34-50 is FR2, the amino acid sequence of positions 51-57 is CDR2, the amino acid sequence of positions 58-95 is FR3, the amino acid sequence of positions 96-111 is CDR3, and the amino acid sequence of positions 112-122 is FR4.

[0077] Example 2

[0078] Preparation of Nanobody 2F5

[0079] (1) Amplification of the original strain TG1 of the nanobody and transformation of the recombinant plasmid of the nanobody into Escherichia coli BL21 (DE3)

[0080] 1) The original strain TG1 glycerol bacteria containing the nanobody nucleic acid was inoculated into 5 ml of fresh LB-A medium at a ratio of 1:1000 and cultured overnight at 37°C and 200 rpm;

[0081] 2) The next day, use Plasmidminikit (OMEGA) to extract plasmid according to the instructions;

[0082] 3) After verification, transform 1 μl of the above plasmid into 100 μl competent cells, mix gently, place on ice for 30 min, heat shock in a 42°C water bath for 90 s, and cool in an ice bath for 3 min;

[0083] 4) Add 600 μl of LB medium to the centrifuge tube, shake and culture at 37°C for 60 min, take 100 μl of the supernatant, spread it on an LB-A plate using a triangular spreader, and culture inverted at 37°C overnight.

[0084] (2) Inducible expression of nanobodies

[0085] 1) Pick the above monoclonal colony and culture it in LB-A medium at 37°C with shaking overnight;

[0086] 2) The next day, the bacterial solution was added to 100 ml of fresh LB-A medium at a ratio of 1:100, and cultured at 37°C with shaking for 3 h until the bacterial solution OD600 = about 0.8, and 1 mM IPTG was added, and induced at 30°C overnight;

[0087] 3) On the third day, centrifuge at 8000 rpm for 10 min to collect the cells, add 1.5 ml of pre-cooled TES buffer to resuspend the precipitate, place on ice for 2 min, and gently shake for 30 s. Repeat this cycle 6 times, add 3.0 ml of TES / 4 (dilute TES 4 times with water), gently shake for 30 s, place on ice for 2 min, and repeat the shaking and standing steps 6 times in total;

[0088] 4) Centrifuge at 9000 rpm and 4°C for 10 min and collect about 4.5 ml of supernatant (periplasmic extract).

[0089] (3) Purification and identification of nanobodies

[0090] 1) After resuspending IMAC Sepharose (GE), take 2 ml and add it to the gravity column. Let it stand for 30 minutes to allow the sepharose to naturally settle at the bottom of the gravity column and the storage buffer to flow out;

[0091] 2) adding 2 column volumes of nickel sulfate solution (0.1 M), and flowing out the nickel sulfate solution at a flow rate of about 8 seconds / drop;

[0092] 3) Add 10 column volumes of equilibration buffer to equilibrate and wash the sepharose, keeping the flow rate unchanged;

[0093] 4) Dilute the sample twice with the equilibration buffer, add it to the gravity column, adjust the flow rate to 6 seconds / drop, and collect the permeate;

[0094] 5) Add 10 column volumes of washing buffer to wash the sepharose, maintain the flow rate unchanged, and collect the washing solution; add 3 column volumes of elution buffer, maintain the flow rate at 6 seconds / drop, and collect the eluate containing the target protein;

[0095] 6) Finally, 10 column volumes of equilibration buffer, 10 column volumes of pure water and 10 column volumes of 20% ethanol were added in sequence to wash the sepharose, and finally 4 ml of 20% ethanol was retained to preserve the column.

[0096] The samples collected above were respectively subjected to SDS-PAGE detection.

[0097] Example 3

[0098] Determination of affinity activity between nanobodies and antigens

[0099] (1) Chip antigen coupling

[0100] The antigen was prepared into a 20 μg / ml working solution with sodium acetate buffer of different pH (pH 5.5, pH 5.0, pH4.5, pH4.0), and a 50 mM NaOH regeneration solution was prepared at the same time. The electrostatic binding between the antigen and the surface of the chip (GE) under different pH conditions was analyzed using the template method in the Biacore T100 protein interaction analysis system instrument. The most neutral pH system was selected and the antigen concentration was adjusted as required as the coupling condition, with the signal increase reaching 5 times RL as the standard. The chip was coupled according to the template method provided in the instrument: the blank coupling mode was selected for channel 1, the Target coupling mode was selected for channel 2, and the target was set to the designed theoretical coupling amount. The coupling process took about 60 minutes.

[0101] (2) Exploration of analyte concentration setting conditions and optimization of regeneration conditions

[0102] Take the manual injection mode, select the 2-1 mode injection for channels 1 and 2, and set the flow rate to 30μl / min. The injection conditions are all 120s, 30μl / min. The regeneration conditions are all 30s, 30μ / min. First, continue to empty the running buffer until all baselines are stable. Prepare a nanoantibody solution with a large concentration span, and configure it with running buffer. It is recommended to set it to 200μg / ml, 150μg / ml, 100μg / ml, 50μg / ml, 20μg / ml, 10μg / ml, and 2μg / ml. Prepare the regeneration solution and select the regeneration solution of four pH gradients of glutamate hydrochloric acid system: 1.5, 2.0, 2.5, and 3.0. Manually inject 200μg / ml analyte sample, observe channel 2, and regenerate from the regeneration buffer with the most neutral pH until the response line of channel 2 after regeneration returns to the same height as the baseline. Manually inject 200μg / ml analyte sample again, observe the signal change of channel 2-1 and record the binding amount. After regeneration with the regeneration solution that finally makes the response line return to the baseline in the previous step, manually inject 200μg / ml analyte sample again, observe the signal change of channel 2-1 and record the binding amount and compare it with the binding amount value just now. If the deviation is less than 5%, the regeneration solution of this pH is considered to be the best regeneration solution. If the binding amount of the second injection is low, continue to experiment with a regeneration buffer of a lower pH. Use the selected best regeneration solution as the chip surface regeneration reagent after each injection. Inject the analyte concentration samples set above respectively, and analyze the binding amount of each concentration to finally determine the concentration gradient required for the affinity test.

[0103] (3) Affinity test

[0104] According to the optimized sample concentration gradient, regenerate the solution, and use the instrument's own template method (where the injection conditions are set to 60s, 30μl / min; dissociation time: 600s; regeneration conditions: 30s, 30μl / min) to test the affinity between the nanobody and the antigen. Observe the signal of the 2-1 channel at any time. The affinity test process takes about 200 minutes.

[0105] (4) Results analysis

[0106] Select several appropriate concentration gradient binding and dissociation curves and use the 1:1 binding mode to fit all curves, and finally obtain the affinity value and important parameters such as binding constant and dissociation constant. The affinity value of anti-RPL19 nanobody 2F5 is 3.082E-09.

[0107] Table 1 Nanobody affinity data

[0108] Sample No. Binding constant Dissociation constant Affinity 1A7 8.736E+04 1.257E-05 1.439E-09 1B1 2.379+04 1.591E-04 6.689E-09 1B7 9.562+04 8.061E-04 8.430E-09 1C5 1.121+04 3.045E-05 2.716E-09 1C8 1.012+04 6.183E-05 6.110E-09 1E9 1.142+04 2.497E-05 2.187E-09 1E11 1.150+04 1.707E-04 1.485E-08 1F9 6.354+03 5.261E-04 8.267E-08 2F5 1.107+04 3.411E-05 3.082E-09 2G10 8495+03 2.228E-05 2.622E-09

[0109] Example 4

[0110] ELISA overlay data analysis of nanoantibodies

[0111] (1) Determination of antigen saturation concentration

[0112] Coat the antigen at a concentration of 2μg / ml, 100μl / well, coat at 4℃ for 24h, and wash the plate 5 times. Block overnight with 1% BSA as a blocking agent and wash the plate 5 times. Add nanoantibodies of different gradient dilutions, negative controls (negative serum 1:100), and PBS blank controls to the ELISA plate, incubate at 37℃ for 30min, and wash the plate 5 times. Add HRP-labeled goat anti-alpaca IgG diluted at a ratio of 1:4000, incubate at 37℃ for 30min, and wash the plate 5 times. Add TMB colorimetric solution, incubate at 37℃ for 10min, and terminate the reaction with 2M sulfuric acid. Read the absorbance at 450nm, draw the antibody saturation curve, and select the concentration at which the reading no longer increases with increasing concentration as the saturation concentration according to the results.

[0113] (2) Site superposition experiment

[0114] First add the first antibody to react, then add the second antibody after washing the plate, then add the enzyme-labeled secondary antibody after washing the plate, and read the colorimetric reading with TMB (the method is the same as above). Calculate the overlap rate AI of the two antibodies. AI>50% indicates that the antigenic sites of the two antibodies tested are different, and AI<50% indicates that the antigenic epitopes of the two antibodies tested are the same. The larger the AI ​​value, the lower the possibility of site overlap. The formula is: AI = [2×A(1+2)-(A1+A2)] / A(1+2)×100%

[0115] A1—First Antibody Reading

[0116] A2—Second Antibody Reading

[0117] A(1+2)—Superposition of 2 antibody readings

[0118] Table 2 Antibody-antigen epitope superposition experiment

[0119]

[0120] The experimental results are shown in Table 2. 2F5 and the other four nanoantibodies 1A7, 1C5, 1F9, and 1B1 target different antigenic epitopes of the RPL19 antigen, respectively. This indicates that in the detection application of RPL19, the probability of these five nanoantibodies forming a detection antibody pair is greatly increased, thereby increasing the detection efficiency.

[0121] Example 5

[0122] Analysis of Nanobody Binding Sites Using Biacore

[0123] The main principle of the Biacore system is to shift the SPR (refractive index) by changing the concentration of surface molecules, which is reflected as a change in the RU value on the monitor. Due to the higher sensitivity of the system, we designed relevant experiments to verify the experimental results of ELISA superposition. First, repeat the injection of the first nanoantibody A twice, observe the change in RU value to confirm the saturation of the corresponding antigen binding site and record it; then enter the second nanoantibody B, observe and record the RU value: if the RU value is no more than 20% different from the RU value of the single nanoantibody B, it can be considered that the two recognize different antigenic determinants; if the difference value exceeds 20% but is less than 60%, it is considered that the two have a steric effect; if the difference value exceeds 60%, it is determined that the two recognize the same antigen. The specific operation is to first simply inject antibody B to record the RU increase value RB1 and regenerate the chip; then repeat the injection of antibody A twice, record the RU increase value RA, and after confirming saturation, directly inject antibody B and observe the increase in RU value RB2; then use the formula (RB2-RA) / RB1 to calculate the steric rate to determine whether the two recognize the same antigenic determinant.

[0124] Table 3 RU value changes in Biacore detection of nanoantibody superposition experiment

[0125]

[0126] The results are shown in Table 3. It can be seen that the 2F5 nanobody and the other four nanobodies all recognize different antigenic sites, which is consistent with the results inferred from the ELISA superposition experiment. This further verifies the application prospects of the five nanobodies in the field of RPL19 detection.

[0127] Example 6

[0128] Application of 2F5 in detecting RPL19 content in standard serum

[0129] The binding site sequence of human alkaline phosphatase is used as the amino acid sequence of the chemiluminescent region, as shown in SEQ ID NO:8. 1C5 or 1A7 nanobody is used as the secondary antibody, and its variable region sequence contains the amino acid sequence as described in SEQ ID NO.6 or SEQ ID NO.7, so that it is fused with the luminescent region through a flexible polypeptide to become a nanobody 1C5-HAP or 1A7-HAP with a chemiluminescent region sequence, and its amino acid sequence is shown in SEQ ID NO:9 or SEQ ID NO:10. Two restriction sites HindⅢ and EcoRI are added to the two ends of the nucleic acid coding sequence, and the two restriction sites are connected to the vector pCDNA3.1(+). After the endotoxin-free plasmid is extracted, it is transfected with 293 cells in logarithmic growth. After the transfected cells are cultured for 36 hours, the cell culture fluid is poured into a 50ml centrifuge tube, centrifuged at 12000g for 5 minutes, the supernatant is collected, filtered with a 0.22μm filter membrane, and the culture supernatant is purified by anion exchange chromatography. The affinity test of 1C5-HAP and 1A7-HAP was performed using the same method as in Example 3. The results showed that the affinity value of 1C5-HAP was 1.864E-10, and the affinity value of 1A7-HAP was 7.462E-10. After screening and pairing, the results are shown in Table 4. FC-fused nanoantibody 2F5 was selected as the capture primary antibody (the fusion method is shown in Example 5 in CN106749667A), and its amino acid sequence is shown in SEQ ID NO.12. 1C5-HAP was used as the enzyme-labeled secondary antibody to perform double antibody sandwich immunoassay to detect RPL19 antigen in serum samples, and an excellent detection effect was obtained. The specific process is as follows:

[0130] Use sterile CBS to dilute the capture antibody to a final concentration of 10μg / ml; add 100μl to each well of a 96-well ELISA plate and let stand at 4℃ for 18h; discard the supernatant, add 300μl of washing solution to each well, shake horizontally for 3min, and discard the supernatant; repeat the plate wash four times. Add 200μl of 1% BSA to each well and let stand at 37℃ for 1h. Repeat the plate wash four times; add 50μl of positive control, negative control or sample to be tested to each well; then add 50μl of freshly diluted enzyme-labeled secondary antibody (i.e. nanoantibody 1C5-HAP or 1A7-HAP, diluted to a working concentration of 2μg / ml) to each well, shake on a shaker for 3-5s; incubate at 37℃ for 1h. Wash the plate four times, add 100 μl AP chemiluminescence colorimetric solution (BM Chemiluminescence ELISA Substrate) to each well, shake on a shaker for 3-5 seconds, incubate at room temperature in the dark for 10 minutes, select the ELISA program Luminescence, measure the Lum value of each well and calculate the RPL19 value of the quality control serum. Results The linear index R2 of 1C5 and 2F5 nanoantibodies was greater than 0.99.

[0131] Table 4 Results of linear index of the curve of RPL19 content in serum detected by pairing of Nanobody 2F5 with Nanobody 1C5 and 1A7

[0132] Capture Antibody Detection antibodies Linearity index (R2) 2F5 1C5-HAP 0.9935 2F5 1A7-HAP 0.9771

[0133] This example shows that when 2F5 is paired with 1C5, the linear index approaches 1, and an excellent detection effect is achieved, indicating that it has a low overlap with the nano antibody 1C5 in the antigen recognition epitope. This property ensures that the nano antibody provided by the present invention is used as a capture primary antibody and a specifically adapted enzyme-labeled secondary antibody in the method for detecting RPL19 by double antibody sandwich immunoassay.

[0134] Example 7 Determination of ADCC activity induced by anti-RPL19 nanobody 2F5 with constant region

[0135] HCC-9204 and SK-Hep-1 cells (3×104 / well) were cultured in a 96-well cell culture plate for 48 hours, and then LAK cells (lymphokine activated killer cells), anti-RPL19 nanoantibodies or IgG antibody controls were added according to specific ratios. The ratio of LAK cells to target cells was 1:1, 5:1, 10:1, 15:1, 20:1, and the antibody concentration was 2μg / ml. Incubate at 37°C for 6 hours in a 5% CO2 environment, remove LAK cells and dead tumor cells, and use the MTS method to measure cell viability.

[0136] Cytotoxicity (%) = [OD490 of experimental target cells / OD490 of control target cells] × 100. The results showed that the anti-RPL19 nanoantibody 2F5 could significantly induce the ADCC activity of LAK cells, and the tumor cell lysis rate was about 55%. This lysis phenomenon was not observed in SK-Hep-1 cells that do not express RPL19.

Claims

1. A nanobody against RPL19, characterized in that The amino acid sequence of the Nanobody is shown in SEQ ID NO:

1.

2. A nucleic acid, characterized in that The nucleic acid is: a nucleic acid encoding the antibody according to claim 1. An expression vector comprising the nucleic acid according to claim 2. A host cell comprising the expression vector according to claim 3.

Citation Information

Patent Citations

  • Nanobody resisting CEA (carcinoembryonic antigen) and application of nanobody

    CN106749667A

  • Polypeptide-human protein 9 containing characteristic sequence fragment of ribosomal protein L19 and polynucleotide for coding it

    CN1320639A

  • Means and methods for identifying ribosome associated RNA molecules

    EP2917363A1